OCS
Price
$17.71
Change
+$0.06 (+0.34%)
Updated
Jul 25 closing price
Capitalization
903.81M
SNSE
Price
$6.98
Change
-$0.18 (-2.51%)
Updated
Jul 25 closing price
Capitalization
8.8M
4 days until earnings call
Interact to see
Advertisement

OCS vs SNSE

Header iconOCS vs SNSE Comparison
Open Charts OCS vs SNSEBanner chart's image
Oculis Holding AG
Price$17.71
Change+$0.06 (+0.34%)
Volume$5.91K
Capitalization903.81M
Sensei Biotherapeutics
Price$6.98
Change-$0.18 (-2.51%)
Volume$7.6K
Capitalization8.8M
OCS vs SNSE Comparison Chart in %
Loading...
OCS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SNSE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
OCS vs. SNSE commentary
Jul 28, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is OCS is a StrongBuy and SNSE is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 28, 2025
Stock price -- (OCS: $17.71 vs. SNSE: $6.98)
Brand notoriety: OCS and SNSE are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: OCS: 28% vs. SNSE: 72%
Market capitalization -- OCS: $903.81M vs. SNSE: $8.8M
OCS [@Biotechnology] is valued at $903.81M. SNSE’s [@Biotechnology] market capitalization is $8.8M. The market cap for tickers in the [@Biotechnology] industry ranges from $313.33B to $0. The average market capitalization across the [@Biotechnology] industry is $2.57B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

OCS’s FA Score shows that 0 FA rating(s) are green whileSNSE’s FA Score has 1 green FA rating(s).

  • OCS’s FA Score: 0 green, 5 red.
  • SNSE’s FA Score: 1 green, 4 red.
According to our system of comparison, SNSE is a better buy in the long-term than OCS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

OCS’s TA Score shows that 4 TA indicator(s) are bullish while SNSE’s TA Score has 5 bullish TA indicator(s).

  • OCS’s TA Score: 4 bullish, 5 bearish.
  • SNSE’s TA Score: 5 bullish, 5 bearish.
According to our system of comparison, both OCS and SNSE are a good buy in the short-term.

Price Growth

OCS (@Biotechnology) experienced а +1.20% price change this week, while SNSE (@Biotechnology) price change was -10.97% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +7.60%. For the same industry, the average monthly price growth was +17.32%, and the average quarterly price growth was +27.29%.

Reported Earning Dates

SNSE is expected to report earnings on Jul 31, 2025.

Industries' Descriptions

@Biotechnology (+7.60% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
OCS($904M) has a higher market cap than SNSE($8.8M). OCS YTD gains are higher at: 4.176 vs. SNSE (-28.790). OCS has less debt than SNSE: OCS (1.1M) vs SNSE (3.21M).
OCSSNSEOCS / SNSE
Capitalization904M8.8M10,275%
EBITDA-101.78MN/A-
Gain YTD4.176-28.790-15%
P/E Ratio63.06N/A-
Revenue0N/A-
Total Cash182MN/A-
Total Debt1.1M3.21M34%
TECHNICAL ANALYSIS
Technical Analysis
OCSSNSE
RSI
ODDS (%)
Bullish Trend 3 days ago
90%
Bullish Trend 3 days ago
83%
Stochastic
ODDS (%)
Bullish Trend 3 days ago
50%
Bullish Trend 3 days ago
90%
Momentum
ODDS (%)
Bearish Trend 3 days ago
41%
Bearish Trend 3 days ago
90%
MACD
ODDS (%)
N/A
Bearish Trend 3 days ago
90%
TrendWeek
ODDS (%)
Bullish Trend 3 days ago
51%
Bearish Trend 3 days ago
90%
TrendMonth
ODDS (%)
Bearish Trend 3 days ago
48%
Bearish Trend 3 days ago
90%
Advances
ODDS (%)
Bullish Trend 5 days ago
70%
Bullish Trend 26 days ago
74%
Declines
ODDS (%)
Bearish Trend 12 days ago
63%
Bearish Trend 5 days ago
90%
BollingerBands
ODDS (%)
Bullish Trend 3 days ago
55%
Bearish Trend 4 days ago
90%
Aroon
ODDS (%)
Bearish Trend 3 days ago
57%
Bullish Trend 3 days ago
88%
View a ticker or compare two or three
Interact to see
Advertisement
OCS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SNSE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
GTSIX32.220.24
+0.75%
Invesco Small Cap Growth Inv
RYDKX97.940.43
+0.44%
Rydex Dow Jones Industrial Average® C
SCRUX11.580.04
+0.35%
Invesco Income Advantage U.S. Fund R
FAASX29.990.03
+0.10%
Fidelity Advisor Asset Manager 70% A
PDEQX19.35-0.08
-0.41%
PGIM Jennison Emerging Markets Eq OppsR6

OCS and

Correlation & Price change

A.I.dvisor indicates that over the last year, OCS has been loosely correlated with HURA. These tickers have moved in lockstep 35% of the time. This A.I.-generated data suggests there is some statistical probability that if OCS jumps, then HURA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To OCS
1D Price
Change %
OCS100%
+0.34%
HURA - OCS
35%
Loosely correlated
+0.35%
SNSE - OCS
35%
Loosely correlated
-2.51%
CUE - OCS
33%
Loosely correlated
-2.44%
CGEN - OCS
31%
Poorly correlated
-0.65%
GRI - OCS
29%
Poorly correlated
+1.02%
More

SNSE and

Correlation & Price change

A.I.dvisor indicates that over the last year, SNSE has been loosely correlated with HURA. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if SNSE jumps, then HURA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SNSE
1D Price
Change %
SNSE100%
-2.51%
HURA - SNSE
48%
Loosely correlated
+0.35%
VSTM - SNSE
46%
Loosely correlated
+16.07%
BIORQ - SNSE
45%
Loosely correlated
N/A
MOLN - SNSE
43%
Loosely correlated
-3.29%
GRI - SNSE
39%
Loosely correlated
+1.02%
More